Everything below concerns storage stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Origins of the term == The expression "cold war" was rarely used before 1945. Some writers credit the fourteenth-century Spaniard Don Juan Manuel for first using the term (in Spanish) regarding the conflict between Christianity and Islam; however, the term employed was "tepid" rather than "cold". The word "cold" first appeared in a faulty translation of his work in the 19th century. In 1934, the term was used in reference to a faith healer who received medical treatment after being bitten by a snake. The newspaper report referred to medical staff's suggestion that faith had played a role in his survival as a "truce in the cold war between science and religion". Regarding its contemporary application to a conflict between nation-states, the phrase appears for the first time in English in an anonymous editorial published in The Nation Magazine in March 1938 titled "Hitler's Cold War". The phrase was then used sporadically in newspapers throughout the summer of 1939 to describe the nervous tension and spectre of arms-buildup and mass-conscription prevailing on the European continent (above all in Poland) on the eve of World War II. It was described as either a "cold war" or a "hot peace" in which armies were amassing in many European countries. Graham Hutton, Associate Editor of The Economist, used the term in his essay titled "The Next Peace," published in the August 1939 edition of The Atlantic Monthly (today The Atlantic).
While Switzerland was not officially invited, the President of the Swiss Confederation Guy Parmelin welcomed the heads of state and government of the participating countries at Geneva Airport and attended other venues. The 2026 summit was the first G7 leaders' summit attended by Japanese Prime Minister Sanae Takaichi. The 2026 summit was the final G7 summit attended by French President Emmanuel Macron and British Prime Minister Keir Starmer. The participation of Giorgia Meloni and Sanae Takaichi made it the third time two G7 female leaders were principals in the G7 summit. France invited several non-G7 countries to participate in the summit and in preparatory discussions. Brazil, India, Kenya and South Korea were included as partner countries in the Sherpa track. Macron invited Indian Prime Minister Narendra Modi and Brazilian President Luiz Inácio Lula da Silva to participate in the summit during meetings held around the AI Impact Summit in New Delhi in February 2026. Additional invitations were extended to leaders from Egypt, Qatar, Saudi Arabia, Syria, Ukraine and the United Arab Emirates. Syria had been invited to participate in a G7 summit for the first time. The invitation for Syrian president Ahmed al-Sharaa was hand-delivered to Syrian Finance Minister Mohammed Yisr Barnieh, who attended the group's financial talks in Paris, though al-Sharaa did not ultimately attend. Saudi Arabia's crown prince, Mohammed bin Salman, said that he was unable to attend the summit, citing prior commitments. South Africa was not included among the invited countries.
Molecular pathology is focused upon the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids. Molecular pathology is multidisciplinary by nature and shares some aspects of practice with both anatomic pathology and clinical pathology, molecular biology, biochemistry, proteomics and genetics. It is often applied in a context that is as much scientific as directly medical and encompasses the development of molecular and genetic approaches to the diagnosis and classification of human diseases, the design and validation of predictive biomarkers for treatment response and disease progression, and the susceptibility of individuals of different genetic constitution to particular disorders. The crossover between molecular pathology and epidemiology is represented by a related field "molecular pathological epidemiology". Molecular pathology is commonly used in diagnosis of cancer and infectious diseases. Molecular Pathology is primarily used to detect cancers such as melanoma, brainstem glioma, brain tumors as well as many other types of cancer and infectious diseases. Techniques are numerous but include quantitative polymerase chain reaction (qPCR), multiplex PCR, DNA microarray, in situ hybridization, DNA sequencing, antibody-based immunofluorescence tissue assays, molecular profiling of pathogens, and analysis of bacterial genes for antimicrobial resistance. Techniques used are based on analyzing samples of DNA and RNA. Pathology is widely used for gene therapy and disease diagnosis.
=== Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry (since 1985) === 2021 Veronica M. Bierbaum 2020 Kimberly A. Prather 2019 Jennifer S. Brodbelt 2018 Carol Vivien Robinson 2017 Vicki H. Wysocki 2015 Hilkka I. Kenttämaa 2010 Catherine E. Costello 2008 Catherine C. Fenselau 1990 Marjorie G. Horning
Sources: en.wikipedia.org
=== Dried fruit === Dried fruit is fruit from which the majority of the original water content has been removed, either naturally, through sun drying, or through the use of specialized dryers or dehydrators. Dried fruit has a long tradition of use dating back to the fourth millennium BC in Mesopotamia, and is prized because of its sweet taste, nutritive value, and long shelf life.
=== Asia === Internal border controls exist in many parts of Asia. For example, travellers visiting minority regions in India and China often require special permits to enter. Internal air and rail travel within non-autonomous portions of India and mainland China also generally require travel documents to be checked by government officials as a form of interior border checkpoint. For such travel within India, Indian citizens may utilise their Voter ID, National Identity Card, passport, or other proof of Indian citizenship, whilst Nepali nationals may present any similar proof of Nepali citizenship. For such travel within mainland China, Chinese nationals must use their national identity cards.
Petri dish A shallow, transparent plastic or glass dish, usually circular and covered with a lid, which is widely used in biology laboratories to hold solid or liquid growth media for the purpose of culturing cells. They are particularly useful for adherent cultures, where they provide a flat, sterile surface conducive to colony formation from which scientists can easily isolate and identify individual colonies.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.